Tabrecta

Tabrecta (Capmatinib) is an oral prescription therapy for adults with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. It targets MET-driven tumor growth with precision. Seek medical guidance before use. Short-term storage at room temperature advised.

Tabrecta (Capmatinib) is prescribed for adults with metastatic non-small cell lung cancer (NSCLC) when the cancer shows MET exon 14 skipping mutations. It is designed to block MET protein activity that drives tumor growth. This targeted therapy is used when standard treatments are not suitable. Patients should discuss suitability with their oncologist.

Tabrecta (Capmatinib) works by interfering with MET protein signals that cancer cells rely on to grow and spread. Many patients notice disease stabilization or tumor shrinkage over time. Individual responses vary widely based on cancer biology and prior treatments. Regular monitoring helps track progress and adjust care plans.

Keep Tabrecta (Capmatinib) in its original packaging away from moisture and direct light. Store at room temperature, avoiding high humidity areas like bathrooms. Always use the medication exactly as prescribed by your healthcare provider. Do not share this medication with others, even if symptoms seem similar.

Avoid grapefruit and grapefruit juice while taking Tabrecta (Capmatinib), as they may increase side effects. Strong CYP3A inhibitors or inducers can alter how the drug works; discuss all current medications with your doctor. Certain supplements and herbal products may also interact. Alcohol use should be limited and discussed with a healthcare professional.